SAN FRANCISCO (AFX) -- Lucent Technologies remained higher on investors' radar during Monday's after-hours session in anticipation of a merger deal, while DexCom Inc. slipped after a regular-session gain on FDA approval for a diabetes device.
The Nasdaq-100 After Hours Indicator, which tracks the evening trading direction of the index's leading technology stocks, rose 0.23 points to 1,680.86.
Lucent Technologies Inc. was the second most actively traded stock on Instinet, but shares kept near their regular-session closing price at $3.08.
The possibility of a merger between telecommunications company Lucent and Alacatel SA could become clearer later this week as Alcatel's board is expected to meet Thursday.
Ciena Corp. tacked on almost 1% to $5.27 as investors kept other telecommunications stocks in their sights.
Meanwhile, DexCom Inc. shares slipped 20 cents to $21. Shares jumped 7% earlier after the company said the Food and Drug Administration has approved a device which allows diabetes sufferers to monitor their blood sugar levels.
The device uses a wire-like sensor inserted under the skin, which transmits data to a receiver.
Shares of Encyte Pharmaceuticals Inc. continued to lose their value by falling 10 cents from its $4.48 regular-session close.
Encyte shares lost nearly half their value earlier today after the drugmaker said the FDA sent notice that it has 'concerns and observations that must be satisfied' before it could win approval for Thelin, a drug to treat hypertension. This story was supplied by MarketWatch. For further information see www.marketwatch.com.
The Nasdaq-100 After Hours Indicator, which tracks the evening trading direction of the index's leading technology stocks, rose 0.23 points to 1,680.86.
Lucent Technologies Inc. was the second most actively traded stock on Instinet, but shares kept near their regular-session closing price at $3.08.
The possibility of a merger between telecommunications company Lucent and Alacatel SA could become clearer later this week as Alcatel's board is expected to meet Thursday.
Ciena Corp. tacked on almost 1% to $5.27 as investors kept other telecommunications stocks in their sights.
Meanwhile, DexCom Inc. shares slipped 20 cents to $21. Shares jumped 7% earlier after the company said the Food and Drug Administration has approved a device which allows diabetes sufferers to monitor their blood sugar levels.
The device uses a wire-like sensor inserted under the skin, which transmits data to a receiver.
Shares of Encyte Pharmaceuticals Inc. continued to lose their value by falling 10 cents from its $4.48 regular-session close.
Encyte shares lost nearly half their value earlier today after the drugmaker said the FDA sent notice that it has 'concerns and observations that must be satisfied' before it could win approval for Thelin, a drug to treat hypertension. This story was supplied by MarketWatch. For further information see www.marketwatch.com.